by Mark Curtis | Nov 24, 2015
Welcome to your Cell Therapy Deal Review for the month of October. Lion Biotechnologies and Kite Pharma both made deals with the National Institutes of Health (NIH) that significantly expanded their respective pipelines. Kite also announced a research collaboration...
by David Kent | Nov 16, 2015
The United Kingdom has begun its foray into using cells derived from human embryonic stem cells (ESCs) in clinical settings. I have to admit I was surprised that following coverage on the BBC and in The Guardian, there was virtually no anti-ESC protesting to be found,...
by Nicole Kuchinsky | Nov 3, 2015
At one point or another we’ve all experienced a bad haircut. We get over such minor annoyances secure in the knowledge that “it will grow back.” The ability of our hair to grow back is based on the amazing capacity of the hair follicle to undergo continuous cycles of...
by Mark Curtis | Oct 27, 2015
Welcome to your Update from the Clinic for the month of September. OncoSec Medical released some initial data from its Phase 1/2 study investigating ImmunoPulse IL-12 DNA in a rare skin cancer. Pluristem and the National Institute of Allergy and Infectious Diseases...
by Mark Curtis | Oct 20, 2015
. Welcome to your Cell Therapy Deal Review for the month of September. Aduro Biotech went the way of Juno and Kite and bought an antibody discovery platform. Intrexon and ZIOPHARM entered into an agreement to develop a novel Treg-based immunotherapy for GvHD. Kite...
Comments